Litcius/Paper detail

Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces

Delphine Lapaillerie, Cathy Charlier, Veronique Guyonnet‐Dupérat, Émilie Murigneux, Henrique S. Fernandes, Fábio G. Martins, Rita P. Magalhães, Tatiana F. Vieira, Clémence Richetta, Frédéric Subra, Samuel Lebourgeois, Charlotte Charpentier, Diane Descamps, Benoît Visseaux, Pierre Weigel, Alexandre Favereaux, Claire Beauvineau, Frédéric Buron, Marie‐Paule Teulade‐Fichou, Sylvain Routier, Sarah Gallois‐Montbrun, Laurent Meertens, Olivier Delelis, Sérgio F. Sousa, Vincent Parissi

2022Antimicrobial Agents and Chemotherapy18 citationsDOIOpen Access PDF

Abstract

) between 0.1 and 0.5 μM depending on the cell lines. Molecular docking calculations of the interaction parameters of the molecules within the S/ACE2 complex from both wild-type and circulating variants of the virus showed that the molecules may target multiple sites within the S/ACE2 interface. Our work indicates that AB-00011778 constitutes a good tool for modulating this interface and a strong lead compound for further therapeutic purposes.

Topics & Concepts

In silicoViral replicationViral entryInfectivityDocking (animal)Virtual screeningVirusCell cultureCoronavirusChemistryVirologyBiologyProtein–protein interactionDrug discoveryCell biologyBiochemistryCoronavirus disease 2019 (COVID-19)GeneticsGeneInfectious disease (medical specialty)MedicineDiseaseNursingPathologySARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesSARS-CoV-2 detection and testing
Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces | Litcius